Nanoligent

What Nanoligent does

Nanoligent is a preclinical-stage Spanish biotech company founded in 2017 as a spin-off from the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. The company is headquartered in Bellaterra (Cerdanyola del Vallès), Barcelona, and employs between 11 and 50 staff. Its stated mission is to research and develop targeted cancer therapeutics using proprietary nanobiotechnology.

The company's core technology is the NanoPrecision Platform, which designs protein conjugates organized as nanoparticles capable of selectively targeting specific biological systems. The platform uses state-of-the-art protein engineering combined with humanized scaffolds that remain highly stable upon in vivo administration, enabling long-lasting systemic circulation and site-specific drug delivery while minimizing undesired immune responses. Its lead candidate, NNL1524, is a multivalent cytotoxic nanoparticle designed to selectively target the chemokine receptor CXCR4 — a receptor overexpressed in more than 20 tumor types including colorectal, lung, breast, and hematologic malignancies — and has demonstrated significant single-agent antitumor activity and a favorable safety profile in preclinical studies.

Nanoligent operates a pre-revenue, partnership-oriented business model. It does not currently sell commercial products; instead, it intends to generate revenue through eventual licensing agreements, milestone payments, and co-development partnerships with pharmaceutical companies for global commercialization. To support this strategy, the company has raised approximately €15.8M cumulatively across seed and Series A rounds, and participates in industry partnering events (PEGS Europe, BioFIT, MEET2WIN, Healthcare Investment Forum). It is governed by a Board of Directors comprising representatives from founding scientists and institutional investors including Inveready, CDTI Innvierte, Clave Capital, i&i Biotech Fund I, Italian Angels for Growth, and AVANTECA Partners.

Name

Nanoligent

Legal name

Nanoligent S.L.

Website

https://nanoligent.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Nanoligent is a preclinical-stage Spanish biotech developing targeted cancer nanodrugs using its proprietary NanoPrecision protein nanoparticle platform. Its lead candidate NNL1524 selectively targets the CXCR4 receptor overexpressed in 20+ tumor types, with future revenue expected from licensing and pharmaceutical partnerships.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAIACAA

Oncology Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Targeted drug delivery
• Cancer nanomedicine
• Protein nanoparticles
• Precision oncology therapeutics
• CXCR4 receptor targeting

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Development and Commercialization: Pre-revenue biotech company developing targeted nanodrugs for cancer treatment. Revenue will be generated through eventual drug commercialization, licensing agreements, and/or partnerships with pharmaceutical companies for co-development and commercialization rights.
2. Licensing and Co-development Agreements: Future revenue streams expected from licensing their proprietary nanobiotechnology platform to pharmaceutical partners, co-development partnerships, and milestone payments tied to clinical development progress.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Nanoligent is a preclinical-stage biotech company developing targeted nanodrugs for cancer treatment using its proprietary NanoPrecision protein-conjugate nanoparticle platform. Its lead candidate NNL1524 is a multivalent cytotoxic nanoparticle that selectively targets the CXCR4 chemokine receptor overexpressed in 20+ metastatic cancer types, designed to eliminate cancer cells while sparing healthy tissue with minimal toxicity. Future commercialization is expected via licensing and co-development partnerships with pharmaceutical companies.

Product overview

Nanoligent is a biotech company developing targeted nanodrugs for cancer treatment using its proprietary NanoPrecision Platform. The platform enables the design of protein conjugates organized as nanoparticles for precise targeting of cancer cells. The lead product candidate is NNL1524, a multivalent cytotoxic nanoparticle targeting CXCR4, designed to selectively eliminate cancer cells while sparing healthy tissue, with minimal toxicity. The technology has potential applications across multiple cancer types including colorectal, lung, breast, and hematologic malignancies.

Differentiator

Problem solved

Functional benefit

Products and services

• NNL1524 Multivalent cytotoxic nanoparticle designed to selectively target the chemokine receptor CXCR4, a protein involved in tumor growth, invasion, and metastasis frequently overexpressed in hematologic and solid malignancies including colorectal, lung, and breast cancers. Demonstrated significant antitumor activity as a single agent and favorable safety profile in preclinical studies; intended for patients with CXCR4-overexpressing metastatic tumors.
• NanoPrecision Platform

Quantifiable outcome

• Significant antitumor activity demonstrated as single agent in preclinical studies
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• Universitat Autònoma de Barcelona (UAB)coreStrategic or Co-development PartnerHome institution spin-off origin. Co-founders Dr. Villaverde and Dr. Vázquez from the Nanobiotechnology Group at Institute of Biotechnology and Biomedicine (IBB). Provides research facilities and academic expertise.
• Institut de Recerca Sant Pau (IIB Sant Pau)coreStrategic or Co-development PartnerResearch institute spin-off origin. Dr. Mangues heads the Oncogenesis and Antitumor Drug Group. Provides clinical research expertise and facilities.
• CIBER-BBNmajorStrategic or Co-development PartnerCIBER of Bioengineering, Biomaterials, and Nanomedicine - national research network providing scientific collaboration and expertise.
• IBB-UAB (Institut de Biotecnologia i de Biomedicina)coreStrategic or Co-development PartnerResearch institute providing protein engineering and nanobiotechnology expertise. Home of the Nanobiotechnology Group co-led by Villaverde and Vázquez.
• IBEC (Institute for Bioengineering of Catalonia)majorStrategic or Co-development PartnerCollaborated in organizing Bioengineering and Medtech against Cancer short course under B·Debate framework.
• Nanotechnology Characterization LaboratoryminorStrategic or Co-development PartnerProvides nanotechnology characterization services for nanomedicine development.
• CSIC (Consejo Superior Investigaciones Científicas)minorStrategic or Co-development PartnerSpanish national research council providing additional research infrastructure and expertise.
• CIEMATminorStrategic or Co-development PartnerSpanish research organization providing additional scientific collaboration capabilities.
• ENG4BIOminorStrategic or Co-development PartnerCollaborating institutional partner providing research and development support.
• Arquímedes AcceleratorminorImplementation/ SI/ Consulting PartnerIntensive growth program in collaboration with Santander Bank (Universidades section). Provided specialized training in financial strategy, technology monitoring, IP, taxation, legal aspects, and financing over two months.
• FarmaindustriaminorStrategic or Co-development PartnerSpanish pharmaceutical industry employers' organization. Hosted Nanoligent at XVIII Farma-Biotech Cooperation Meeting to boost pre-clinical research and potential industry partnerships.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Emergence Therapeutics: European biotech developing CXCR4-targeted antibody-drug conjugates (lead asset NBE-002). Most direct peer to Nanoligent because both pursue CXCR4 as the targeting receptor for cytotoxic nanoparticle/conjugate therapeutics in oncology.

Emerging players

• Bicycle Therapeutics: Clinical-stage biotech using bicyclic peptide scaffolds to create targeted cytotoxic conjugates (BT8009 targets Nectin-4, BT5528 targets EphA2). Highly comparable as it builds toxin-conjugated precision medicines using non-antibody scaffolds — directly competing with NanoPrecision's nanoparticle architecture for next-gen targeted payload delivery.
• Molecular Partners: Clinical-stage Swiss biotech developing Designed Ankyrin Repeat Proteins (DARPins) as precision oncology therapeutics, including targeted cytotoxic conjugates. Comparable as it uses engineered non-antibody protein scaffolds to build selective, stable targeted therapeutics — the same architectural philosophy as NanoPrecision.
• Heidelberg Pharma: German biotech commercializing amanitin-based antibody-drug conjugates and proprietary ATAC platform. Comparable as an early clinical-stage company advancing next-generation targeted cytotoxic conjugates with novel payloads and linkers, addressing the same opportunity Nanoligent targets with its nanoparticle platform.
• Araris Biotech: Swiss preclinical-stage biotech developing site-specific ADCs using a transglutaminase-based linker technology. Comparable as a venture-backed European biotech with a novel targeted-conjugate platform aimed at improving stability and therapeutic index — directly adjacent to NanoPrecision's value proposition.
• Tubulis: German biotech developing next-generation ADCs with proprietary Tub-tag and P5 conjugation chemistries. Comparable as a European Series A/B-stage ADC innovator working to overcome limitations of first-generation ADCs — the same white space Nanoligent's NanoPrecision platform addresses.
• CytomX Therapeutics: Clinical-stage US biotech developing Probody platform — masked antibodies conditionally activated in tumor microenvironments. Comparable as a platform company engineering precision oncology therapeutics that minimize off-target toxicity, paralleling NanoPrecision's targeted delivery thesis.

Broad incumbents

• Mersana Therapeutics: Clinical-stage US biotech with multiple ADC platforms (Dolasynthen, Immunosynthen) and a broader pipeline than Nanoligent. Comparable as a focused next-gen ADC developer and a relevant benchmark for the targeted cytotoxic delivery space Nanoligent is entering.
• Innate Pharma: Clinical-stage French immuno-oncology company with prior CXCR4-targeting programs and active partnerships with Sanofi and AstraZeneca. Comparable because of historical CXCR4 portfolio activity and as a relevant French/EU oncology biotech at a similar stage to Nanoligent.

Regional players

• Ability Pharmaceuticals: Spanish clinical-stage oncology biotech developing small-molecule lipid signaling modulators (e.g., ABTL0812). Comparable as a Spanish biotech at a comparable development stage targeting oncology indications — useful for regional context, talent pool overlap, and Spanish VC ecosystem benchmarking.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nanoligent

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanoligent